生命科学

Our What’s Next: Life Sciences at a Crossroads webinar series helps biotech and life sciences companies navigate today’s volatile markets and prepare for what’s next.

Your go-to resource for tech and life sciences IPOs.

The life sciences industry showed strong resilience in 2024, marked by increased IPO and M&A activity as big pharma sought to expand pipelines amid favorable valuations.

Our in-depth analysis of trends in securities class action filings in the life sciences industry, including highlights from important court decisions.

The last year (and particularly the last few months) of the Biden Administration brought a flurry of activity from the Federal Trade Commission (FTC) in the life sciences space, continuing a yearlong pattern of close scrutiny and culminating most notably in the issuance of a complaint against the leading pharmacy benefit managers (PBMs). It was not all bad news, however, as 2024 still featured several notable deal clearances, including the long-awaited approval of the Novo Holdings / Catalent deal and clearances of multiple transactions involving radiopharmaceutical, neurology, and obesity/diabetes assets.